S-1/A: Caring Brands Seeks NASDAQ Listing, $4M Public Offering

Caring Brands, Inc. filed an S-1/A for a public offering of 1,000,000 shares and a resale of 2,610,000 shares, contingent on a NASDAQ listing, while reporting significant operating losses and a going concern doubt.

Summary

• Caring Brands, Inc. is a wellness consumer products company offering OTC and cosmetic products for hair loss, eczema, psoriasis, vitiligo, and jellyfish sting protection.
• The company is pursuing a public offering of 1,000,000 shares of common stock at an assumed price of $4.00 per share, aiming to raise $3,200,000 in net proceeds after underwriting discounts and expenses.
• A concurrent resale offering of up to 2,610,000 shares by selling stockholders is also registered, which will not provide direct proceeds to the company, but warrant exercises could yield approximately $6,330,000.
• Listing on The Nasdaq Capital Market (NASDAQ) under the symbol CABR is a contingency for consummating both offerings; currently, the common stock trades on OTCQB under CBRA.
• The company reported a net loss of $(1,199,353) for the six months ended June 30, 2025, and $(862,791) for the period from April 24 to December 31, 2024, with nominal revenue.
• Caring Brands has a working capital deficiency and its financial situation raises substantial doubt about its ability to continue as a going concern.
• Key products include Photocil (for vitiligo and psoriasis), Hair Enzyme Booster (JW-700, to enhance minoxidil efficacy), CB-101 (eczema treatment), and NoStingz (sunscreen with jellyfish sting protection).
• Photocil and NoStingz were previously removed from the U.S. market due to insufficient sales and marketing, with relaunch efforts targeted for 2026 and an unspecified timeline, respectively.
• Hair Enzyme Booster (JW-700) launched on Amazon in October 2024 and is licensed to Taisho Pharmaceutical Co. in Japan, with a commercial launch expected in 2025.
• The company entered into a Research Collaboration and Non-Exclusive License Agreement with NOVODX Corporation for an Ebola Rapid Test, involving issuance of 3,000,000 restricted common shares and potential milestone payments.
• Proceeds from the public offering are allocated to product development ($1,900,000), legal & compliance ($100,000), repayment of related party loans ($75,000), general & administrative expenses ($250,000), and general working capital ($875,000).

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, minimal revenue, and a 'going concern' doubt from auditors. While it has a pipeline of products with some positive clinical trial results and licensing agreements, the historical inability to achieve significant sales in the U.S. market for previously launched products, coupled with the highly speculative nature of the investment and substantial dilution risks, indicates a very high-risk profile. The reliance on the current offering to fund operations for only 12 months further underscores the precarious financial position.

Positives

• The global phototherapy treatment market is projected to grow from approximately $1.9 billion in 2023 to $3.23 billion by 2033, at a CAGR of around 5.2%.
• The Indian phototherapy market is expected to expand even faster, with an estimated CAGR of approximately 7.8% as of 2023.
• The global psoriasis treatment market was worth approximately $34 billion in the 12 months ending June 2023, with the U.S. accounting for 78% of sales and growing at an 18% CAGR.
• The global psoriasis market is expected to reach $54-67 billion by 2030, with a CAGR of 8-10% from 2023.
• The global vitiligo treatment market was valued at approximately $538.90 million in 2024 and is projected to grow to $807.70 million by 2034, at a CAGR of 4.60%.
• The Hair Enzyme Booster (JW-700) has 2 granted and 5 pending patents and is licensed to Taisho, a $2.6 billion revenue company and Japan's leading seller of minoxidil products, with commercial launch expected in 2025.
• Clinical trials for Photocil demonstrated significant efficacy in treating vitiligo (28% achieved 70% re-pigmentation, p<0.0001) and psoriasis (43% achieved complete clearance, mean 75% lesion clearance, p<0.00012).
• Hair Enzyme Booster (JW-700) clinically showed a 124% increase in sulfotransferase enzyme activity in one trial (p<0.03) and 75% of subjects exhibited hair regrowth in another (p=0.023).
• CB-101 (eczema treatment) in its prior formulation (JW-100) cleared or reduced eczema in clinical studies, with 50% of subjects achieving clear or almost clear with a two-grade improvement (p=0.028).
• The company has secured licensing agreements for Photocil and Hair Enzyme Booster in India and 31 other territories in Africa and the Far East with Cosmofix and San Pellegrino Cosmetics.
• The company has applied to list its Common Stock on The Nasdaq Capital Market (NASDAQ) under the symbol CABR, which could enhance liquidity and investor visibility.
• The company successfully completed a private placement in 2024, raising $2,110,000 gross proceeds, which funded working capital leading up to the offering.

Negatives

• The company has a limited operating history as a standalone public company, making it difficult to accurately evaluate business prospects.
• Caring Brands has incurred recurring losses from operations, with a net loss of $(1,199,353) for the six months ended June 30, 2025, and $(862,791) for the period from April 24 to December 31, 2024.
• The company has a working capital deficiency and its financial situation creates substantial doubt about its ability to continue as a going concern.
• Revenue has been nominal, with $3,056 for the six months ended June 30, 2025, and $465 for the period from April 24 to December 31, 2024.
• Photocil was removed from the U.S. market from December 2022 to February 2023 due to insufficient sales resulting from a lack of a dedicated sales and marketing team.
• NoStingz was removed from the U.S. market from July 2022 to September 2023 due to insufficient sales resulting from a lack of a dedicated sales and marketing team.
• The company's products are highly speculative and involve a high degree of risk, with investors potentially losing their entire investment.
• Raising additional capital may cause significant dilution to existing stockholders and could involve restrictive covenants or relinquishing rights to technologies.
• The concurrent public offering and resale offering could adversely impact the market price, liquidity, and demand for common stock.
• The company's management has limited experience in managing the day-to-day operations of a public company, potentially leading to additional expenses and operational challenges.
• The third clinical trial for Hair Enzyme Booster (JW-700) showed a 32% increase in SULT1A1 enzyme activity but was not statistically significant (p=0.0700).
• The company does not intend to pay dividends for the foreseeable future.

Risks

• The company may be unable to achieve some or all of the benefits expected from the separation from Safety Shot, Inc.
• The company has a limited operating history as a publicly traded company, and historical financial information may not be representative of future results.
• Some directors and executive officers own Safety Shot common stock or hold positions with Safety Shot, which could cause conflicts of interest.
• The company may not have adequate capital to fund its business and may be unable to raise needed additional capital or financing due to market conditions or regulatory reasons.
• The company may not be able to successfully compete against companies with substantially greater resources in the intensely competitive skin care and hair growth product markets.
• The sale of products involves product liability and related risks that could expose the company to significant insurance and loss expenses.
• If the company is unable to develop and maintain its brand and reputation for product offerings, its business and prospects could be materially harmed.
• The company depends heavily on key personnel, and turnover of senior management could harm the business.
• The company is subject to government regulation, and unfavorable changes could substantially harm its business and results of operations.
• Products may not meet health and safety standards or could become contaminated, leading to recalls and liability claims.
• The company must develop and introduce new products to succeed, and there is no assurance of success in selecting, developing, manufacturing, and marketing new products.
• Adverse publicity associated with products or ingredients, or those of similar companies, could adversely affect sales and revenue.
• The company does not have and may never have any products on the market that have been approved by the FDA for the treatment of disease, and future regulatory approvals are uncertain.
• Delays or difficulties in enrolling subjects in clinical trials could delay or prevent regulatory approvals.
• Inability to manufacture products in sufficient quantities or at defined quality specifications, or to obtain regulatory approvals for manufacturing facilities, could hinder development and revenue.
• It is uncertain whether product liability insurance will be adequate to address claims, or that insurance will be affordable or available on acceptable terms in the future.
• If market opportunities for current and potential future drug candidates are smaller than believed, the ability to generate product revenues may be adversely affected.
• Inability to establish relationships with licensees or collaborators to carry out sales, marketing, and distribution functions or to create effective capabilities could prevent successful product marketing.
• The ability to market products in the United States depends on regulatory classification and compliance, and the FDA may disagree with product determinations.
• Commercial success of OTC/Cosmetic product candidates depends on acceptance by physicians, payers, and patients.
• If FDA approval is obtained for product candidates, the company will be subject to various federal and state fraud and abuse laws, which may impact sales, marketing, and education programs.
• Natural disasters and other events beyond control could materially adversely affect the company.
• The company may not meet product development and commercialization milestones.
• Operations in international markets involve inherent risks that may not be controllable.
• Changes in tax laws and unanticipated tax liabilities could adversely affect the effective income tax rate and ability to achieve profitability.
• The company may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• If the company is not able to adequately protect its intellectual property, it may not be able to compete effectively and may not be profitable.
• The intellectual property behind products may include unpublished know-how as well as existing and pending protection, and all protection eventually expires.
• As an emerging growth company, reduced disclosure requirements may make common stock less attractive to investors.
• The requirements of being a public company may strain resources and distract management, particularly after no longer being an emerging growth company.
• Management has limited experience in managing the day-to-day operations of a public company, potentially incurring additional expenses.
• Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.
• Certain stockholders hold a significant percentage of voting securities, which could reduce the ability of minority stockholders to effect certain corporate actions.
• If securities or industry analysts publish inaccurate or unfavorable research, the stock price could decline.
• Issuance of additional common stock or preferred stock may cause the common stock price to decline.
• Common stock may become subject to the SEC's penny stock rules, adversely affecting trading activity.
• Inability to implement and maintain effective internal control over financial reporting could lead to loss of investor confidence.
• The concurrent resale and potential dilution of stockholders' ownership could adversely impact market price, liquidity, and demand for common stock.
• An active, liquid, and orderly trading market for common stock may not develop or be sustained.
• The company may not be able to satisfy NASDAQ listing requirements or obtain/maintain a listing.
• Investing in the company is highly speculative and could result in the entire loss of investment.
• Anti-takeover provisions in the company's charter and bylaws may prevent or frustrate attempts by stockholders to change the board or management.

Future Outlook

The company plans to relaunch Photocil in the U.S. in 2026 and anticipates CB-101 (eczema treatment) to be available online in the U.S. in Q2 2026. Taisho Pharmaceutical Co. is expected to commercially launch the Hair Enzyme Booster (JW-700) in Japan in 2025. The company intends to expand its sales and marketing team, refine online retail strategies, and explore additional sub-licensing opportunities for Photocil in various international markets. Reformulation and stability testing for NoStingz are expected to resume, with a commercial launch timeline yet to be established. The company also plans to seek acquisition opportunities in the branded consumer products space.

Management Comments

• Management believes that phototherapy treatments, used for conditions such as psoriasis and vitiligo, are set for substantial growth globally.
• Management believes that Psoriasis treatment with Photocil may only address a very small fraction of the market in the US and India.
• Management believes India presents a potential opportunity for market expansion for vitiligo treatments.
• Management believes that Vitiligo treatment with Photocil is expected to address only a very small fraction of the total global market.

Industry Context

The company operates in the wellness consumer products industry, specifically targeting the phototherapy, psoriasis, vitiligo, hair growth, and eczema treatment markets. The global phototherapy treatment market is projected to grow from approximately $1.9 billion in 2023 to $3.23 billion by 2033 (CAGR 5.2%), with India's market expanding faster at 7.8% CAGR. The global psoriasis treatment market was valued at $34 billion in June 2023, with the U.S. dominating at 78% of sales and an 18% CAGR, expected to reach $54-67 billion by 2030. The global vitiligo treatment market was $538.90 million in 2024, projected to reach $807.70 million by 2034 (CAGR 4.60%). The minoxidil market was valued at $1.5 billion in 2022 and is expected to grow to $2.5 billion by 2032. The global eczema treatment market was valued at $14 billion in 2022. The company's products aim to differentiate through unique mechanisms of action and clinical benefits in these competitive markets.

Comparison to Industry Standards

• The filing highlights that Photocil allows narrow-band UV rays to target psoriasis with minimal side-effects, positioning it as a potentially more convenient and less side-effect-prone alternative to conventional phototherapy lamp treatments and biologics like IL-23 inhibitors, IL-17 inhibitors, TNF inhibitors, ustekinumab, and Janus kinase inhibitors (e.g., deucravacitinib, ruxolitinib) which can have significant side effects.
• Topical Photocil treatment is presented as more convenient and having fewer side effects compared to other vitiligo treatments such as topical corticosteroids, tacrolimus, and the JAK inhibitor ruxolitinib (Opzelura).
• The Hair Enzyme Booster (JW-700) is differentiated by its ability to improve the efficacy of FDA-approved minoxidil, contrasting with many unapproved nutritional supplements in the hair growth market. The licensing agreement with Taisho, Japan's largest minoxidil supplier, is cited as an indicator of its potential.
• CB-101 (eczema treatment) is positioned as a topical OTC treatment with dual-action relief, and its prior formulation (JW-100) showed potential superiority to existing prescription drugs in clinical studies, addressing the 86% dissatisfaction rate among eczema patients with current treatments.
• The company acknowledges that Photocil's potential market penetration for psoriasis and vitiligo treatments may only address a very small fraction of the total global market, indicating a limited current competitive footprint despite product differentiation.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceeding, nor is its property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of its business.
• None of the directors, officers, or affiliates are involved in a proceeding adverse to the business or have a material interest adverse to the business.

Related Party Transactions

• Safety Shot, Inc. (former parent company) owns 2,500,000 shares of common stock, representing approximately 18.2% of outstanding shares.
• Safety Shot waived an outstanding balance of $275,876 owed by Caring Brands Florida at September 24, 2024, treating it as additional paid-in capital.
• The company entered into a Research Collaboration and Non-Exclusive License Agreement with NOVODX Corporation (a related party, whose CEO was a former director) for an Ebola Rapid Test, issuing 3,000,000 shares of restricted common stock to NOVODX.
• The company invested $500,000 in NOVODX Corporation's private placement, purchasing 25,134 shares of common stock.
• On June 5, 2025, the company entered into a short-term loan agreement with CEO Dr. Glynn Wilson for $50,000 at an 8% interest rate, due November 5, 2025.
• On July 24, 2025, the company entered into a short-term loan agreement with Chairman of the Board Mr. Brian John for $25,000 at an 8% interest rate, due December 24, 2025.
• On August 4, 2025, the company entered into a services agreement with Greentree Financial Group, Inc. for $30,000 and issuance of 200,000 shares of common stock.
• On August 6, 2025, the company entered into a convertible promissory note for $200,000 with Greentree Financial Group, Inc. (a related party), including a 10% annual interest rate, conversion at $2.00 per share or less, a one-time grant of 25,000 shares, and 200,000 warrants.
• On September 5, 2025, the company issued 200,000 shares of common stock to Genesis One Holdings, LLC pursuant to a consulting agreement dated June 20, 2025.
• On September 5, 2025, the company issued 200,000 shares of common stock to Greentree Financial Group, Inc. pursuant to a service agreement dated August 4, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the public offering and potential warrant exercises. Existing shareholders, particularly those who acquired shares at lower prices, will see an immediate increase in net tangible book value, while new investors will experience substantial dilution. The 'going concern' doubt and recurring losses pose a high risk of losing their entire investment.
• **Employees**: The company has four full-time employees, including key executives. Their continued contributions are vital, and the Equity Incentive Plan aims to incentivize them. Management changes, such as the appointment of a new CFO, could impact internal operations.
• **Customers**: The company's product development and relaunch plans for Photocil, CB-101, and NoStingz aim to provide new or improved wellness consumer products for conditions like vitiligo, psoriasis, eczema, and hair loss, potentially offering more treatment options.
• **Creditors**: Related party loans and a convertible promissory note indicate reliance on debt financing. The 'going concern' doubt raises concerns about the company's ability to repay its debts.
• **Regulators (SEC, FDA)**: The company is subject to SEC reporting requirements as a public company and FDA regulations for OTC and cosmetic products. Compliance failures could lead to enforcement actions, product recalls, and reputational damage.

Next Steps

• Complete the public offering and secure NASDAQ listing for common stock.
• Initiate preparation for scaling-up Photocil manufacturing between Q3 and Q4 2025.
• Initiate the FDA registration process for Photocil by Q4 2025.
• Develop a marketing campaign, U.S. market relaunch, and e-commerce platform integration for Photocil between Q4 2025 and Q1 2026.
• Initiate reformulation process for CB-101 in Q4 2025 and complete by Q1 2026.
• Initiate initial production run and clinical testing for CB-101 by Q2 2026.
• Develop marketing materials campaign, U.S. market relaunch, and e-commerce platform integration for CB-101 by Q3 2026.
• Complete reformulation and initiate stability testing for NoStingz by Q4 2025.
• Complete stability testing and initiate FDA registration process for NoStingz by Q1 2026.
• Initiate production run and finalize launch timeline for NoStingz between Q4 2025 and Q1 2026.
• Evaluate market opportunities for the Ebola Rapid Test license.
• Expand sales and marketing team and refine online retail strategies.
• Explore additional sub-licensing opportunities for Photocil in Nepal, Bangladesh, Sri Lanka, Vietnam, Philippines, Malaysia, Cambodia, Laos, Indonesia, UAE, Egypt, Algeria, Tunisia, Congo, Nigeria, Kenya, Thailand, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, and Saudi Arabia.
• Continue preliminary discussions regarding potential licensing opportunities in Europe and South America.
• Seek acquisition opportunities in the branded consumer products space, including additional OTC/cosmetic therapeutic and skin care brands.

Key Dates

Recommendation

Caring Brands, Inc. presents a highly speculative investment opportunity with significant red flags. The company has a limited operating history as a standalone entity, reports recurring and substantial net losses, and generates only nominal revenue. Its auditors have raised 'going concern' doubts, indicating a precarious financial position. While the company possesses a pipeline of products with some positive clinical trial data and licensing agreements, past U.S. market launches for key products (Photocil, NoStingz) failed due to insufficient sales and marketing. The current public offering and concurrent resale will lead to significant dilution for new investors, and the company's cash position is critically low, with the offering proceeds projected to fund operations for only 12 months. The competitive landscape is intense, and the company's ability to effectively commercialize its products and achieve market acceptance remains highly uncertain. Given the high degree of risk, financial instability, and lack of proven commercial success, a seasoned investor would likely recommend selling or avoiding this stock.

Keywords

Wellness Consumer Products, OTC Products, Cosmetic Products, Hair Loss Treatment, Eczema Treatment, Psoriasis Treatment, Vitiligo Solution, Jellyfish Sting Protection, Minoxidil Booster, Photocil, CB-101, NoStingz, Ebola Rapid Test, NASDAQ Listing, Public Offering, SEC Filing, S-1/A, Biopharmaceutical, Dermatology, Intellectual Property, Clinical Trials, Regulatory Compliance, Capital Raise, Emerging Growth Company, Smaller Reporting Company